CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (83,513)	$ (66,649)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	588	251
Amortization of intangibles	64,886	66,241
Amortization of deferred financing costs	1,824	1,961
Accretion of debt discount	2,655	1,436
Interest accretion of notes receivable	0	(127)
Deferred income tax benefit	24	(10,159)
Stock compensation expense	2,080	4,428
Fair market value change in derivative liability	(6,744)	(19,230)
Issuance of stock for inducement	0	19,500
Fair market value change in contingent consideration	(8,958)	(3,596)
Loss on disposal of fixed assets	35	19
Impairment of fixed assets and intangibles	2,388	0
(Increase) decrease in operating assets (excluding effect of acquisitions):
Accounts receivable	16,966	(16,461)
Income tax receivable	3,384	(6,194)
Inventory	1,753	(182)
Prepaid expenses and other assets	635	3,002
Increase (decrease) in operating liabilities (excluding effect of acquisitions):
Accounts payable and accrued expenses	(7,005)	15,019
Accrued allowances	(6,323)	5,354
Interest payable	(5,285)	(2,957)
Other liabilities	(2,280)	(2,551)
Net cash used in operating activities	(22,890)	(10,895)
Cash flows from investing activities:
Acquisition of Zohydro ER®	0	(83,341)
Acquisition of supplier contract	(583)	0
Acquisition of TREXIMET®	0	(2,836)
Payments received on notes receivable	0	4,850
Purchase of software and equipment	(964)	(1,029)
Net cash used in investing activities	(1,547)	(82,356)
Cash flows from financing activities:
Payments on Treximet Secured Notes	(20,406)	(10,013)
Net (payments) drawdowns on credit facilities	(1,000)	2,655
Net proceeds from issuance of Convertible Notes	0	130,000
Payments for financing costs	0	(5,045)
Payment of consent fee	0	(2,150)
Payments on mortgages and capital leases	(50)	(28)
Proceeds from issuance of common stock, net of tax and costs	18,303	276
Shares withheld for the payment of taxes	(24)	(112)
Net cash (used in) provided by financing activities	(3,177)	115,583
Net (decrease) increase in cash and cash equivalents	(27,614)	22,332
Cash and cash equivalents, beginning of period	56,135	34,855
Cash and cash equivalents, end of period	$ 28,521	$ 57,187